The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

Original title: “Freenome colorectal cancer test data improve on earlier results”

The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.

Original title: “AB Science ends 3 studies in multiple sclerosis, other immune conditions”

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

Original title: “Biotech startup funding gap widens despite rebound in VC investment”

GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.

Original title: “GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China”

The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.

Original title: “AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space”

Roche’s decision to discontinue the Ionis-partnered trials came soon after the biotech sustained a late-stage failure in ATTR-CM.

Original title: “Roche scraps 2 Huntington’s studies, handing Ionis more bad news”